other material
confidence high
sentiment neutral
materiality 0.70
Apellis prices public offering of 7.4M shares at $47/sh, raising $350M gross
Apellis Pharmaceuticals, Inc.
- 7,446,809 shares at $47.00 per share; gross proceeds of $350 million.
- Net proceeds estimated at $330.2 million ($379.8 million if underwriters' option fully exercised).
- Offering expected to close March 28, 2022; underwriters have 30-day option for 1,117,021 additional shares.
- J.P. Morgan, Goldman Sachs, and Evercore acting as joint book-running managers.